{"url_path":"/sec/tlsiw/8-k/2026-05-14/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1826667/0001628280-26-035068-index.html","accession_number":"0001628280-26-035068","cik":"0001826667","ticker":"TLSI","issuer_name":"TriSalus Life Sciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1826667/0001628280-26-035068-index.html","primary_entity_key":"0001826667","primary_entity_name":"TriSalus Life Sciences, Inc."},"word_count":280,"has_tables":true,"body_markdown":"Item 5.07Submission of Matters to a Vote of Security Holders.\n\nOn May 14, 2026, TriSalus Life Sciences, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Meeting”).\n\nA total of 41,728,676 shares of our Common Stock, or 67.9% of the total outstanding shares, of our Common Stock were represented at the Meeting. The final voting results for each of the matters submitted to a stockholder vote at the Meeting are set forth below:\n\n1.The two nominees for Directors were elected to serve three-year terms to expire at the annual meeting of stockholders in 2029, as follows:\n\nNomineeFor WithholdBroker Non-Votes\n\nMary Szela31,393,3102,614,2467,721,120\n\nGary Gordon31,339,1612,668,3957,721,120\n\n2.The appointment of Grant Thornton, LLP to serve as our independent registered accounting firm for the fiscal year ending December 31, 2026 was ratified by the stockholder vote:\n\nForAgainst Abstain\n\n41,098,38528,667601,624\n\n3.The proposal to approve, on an advisory basis, a three-year frequency with which the Company should conduct future stockholder advisory votes on named executive officer compensation was approved by the stockholder vote:\n\n1 Year2 Years3 YearsAbstainBroker Non-Votes\n\n12,656,430736,93120,348,386265,8097,721,120\n\nAfter considering the results of the advisory vote, the Board of Directors approved a resolution that the Company will hold future stockholder advisory votes on named executive officer compensation every three years.\n\n4.The proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers was approved by the stockholder vote:\n\nForAgainst AbstainBroker Non-Votes\n\n32,625,0821,206,105176,3697,721,120\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nDate: May 14, 2026\nTriSalus Life Sciences, Inc.\n\nBy:/s/ David Patience\n\nName:David Patience\n\nTitle:Chief Financial Officer"}